• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Integrating of lipophilic platinum(IV)prodrug into liposomes for cancer therapy on patient-derived xenograft model

    2022-06-20 06:19:46ZioLiQingXuXuefengLinKunyiYuLingLinYangjiaLiuZhiqiangYuTiancaiLiuDixianLuo
    Chinese Chemical Letters 2022年4期

    Zio Li,Qing Xu,Xuefeng Lin,Kunyi Yu,Ling Lin,Yangjia Liu,Zhiqiang Yu,*,Tiancai Liu,Dixian Luo

    a Department of Laboratory Medicine,Huazhong University of Science and Technology Union Shenzhen Hospital(Nanshan Hospital),Shenzhen 518000,China

    b Guangdong Provincial Key Laboratory of New Drug Screening,School of Pharmaceutical Sciences,Southern Medical University,Guangzhou 510515,China

    c School of Laboratory Medicine and Biotechnology,Institute of Antibody Engineering,Southern Medical University,Guangzhou 510515,China

    1 These authors contributed equally to this work.

    ABSTRACT Platinum-based anticancer agents such as cisplatin and its analogues are widely used for treating multiple cancers.However,due to the inferior water-solubility,chemoresistance and consequent adverse side effects,their clinical applications are limited.Herein,cholesPt(IV),a lipophilic platinum(IV)prodrug was synthesized for manufacture of CholesPt(IV)-Liposomes aiming to resolve the predefined obstacles encountered by platinum drugs.Following systematic screening,CholesPt(IV)-Liposomes showed a small particle size(105.6 nm),the rapid release of platinum(Pt)ions,and notable apoptosis of cancer cells.In addition,according to the fluidity and safety results of animal experiments in mice,CholesPt(IV)-Liposomes also showed better therapeutic effect,which significantly inhibited the growth of patientderived xenograft tumors of hepatocellular carcinoma with an inhibition ratio of 80.7%,and effectively alleviated the drug toxicity brought by traditional platinum drugs.Overall,this study provides a promising route to enhance the therapeutic efficiency of platinum drugs in cancer treatment.

    Keywords:Lipophilic platinum(IV)prodrug Liposome Cancer therapy Drug delivery Patient-derived xenograft

    Recent years,cancer has become a formidable medical hot issue[1,2].Platinum-based anticancer agents such as cisplatin and its analogues are widely used to treat multiple cancers[3–7].However,the inferior water-solubility,chemoresistance and consequent adverse side effects limit their clinical applications[8–10].Therefore,it is of great clinical significance to develop a novel strategy to improve platinum efficiency and reduce side effects.

    Nanotechnology-based drug delivery systems have been shown to improve the therapeutic efficiency of chemotherapeutics and reduce system toxicity due to their enhanced permeability and retention effect,which are emerging as the next-generation anticancer agents[11–20].As a tempting modality of nanomedicine,liposomes characterized with spherical nano-scaled vesicles from phospholipids(and other lipids),have been intensively explored as drug delivery vehicles with respect to its excellent biocompatibility,capable of avoiding detection by the body’s immune system,specifically,the cells of reticuloendothelial system[21–23].Besides,liposomes are available to facile post chemistry functionalization,such as PEG surface coating(inert in the body)onto liposomes,which entitle prolonged blood retention for improved bioavailability to the targeted tumor[24–26].For example,He and co-workers reported that non-PEGylated formulations were quickly cleared,while non-PEGylated prodrug nanoparticles(PTXS-S-OA/TPGS2kNPs)exhibited persistently high concentrations of PTX in plasma by evading the identification and phagocytosis of reticulo-endothelial system(RES)[27].Nevertheless,the poor molecular affinity of platinum drugs to the lipids imposes diffi-culty to direct incorporation of platinum drugs into the liposomes.To tackle this drawback,we attempted to couple the lipophilic cholesterol to the platinum drugs.Of note,pioneering research advocated the importance of construction of appropriate Pt(IV)prodrugs as rationale alternative to Pt(II)[28–33].In contrast to Pt(II)susceptible to ligand substitution in the extracellular milieu to induce detoxification of Pt(II),the Pt(IV)prodrugs haven been elucidated to impart improved inertness to ligand substitution,consequently lower the extent of platinum sequestration and deactivation en route to the tumor cells.In this respect,we are encouraged to engineer a cisPt(IV)lipophilic prodrug by attaching cisPt(IV)at the terminus of cholesterol[referred as cholesPt(IV)hereafter]for manufacture of liposomes.

    Fig.1.Schematic illustration and characterizations of cholesPt(IV)-functionalized liposome.Liposomes integrated by cholesPt(IV)were prepared by sequential film hydration and extrusion approach.(a)Anchor of cholesPt(IV)into the lipid bilayer of liposome to yield CholesPt(IV)-Liposome.(b)Integration percentage of cholesPt(IV)as a function of varying feed ratios of cholesPt(IV)/lipids.(c)Representative DLS result of cholesPt(IV)integrated liposome at the identified feed ratio of cholesPt(IV)/lipid of 0.4:1.(d)Colloidal stability of CholesPt(IV)-Liposome(at the identified feed ratio of cholesPt(IV)/lipid ratio of 0.4:1).The size derivation of the formulated liposome was monitored by DLS measurement.

    Herein,cholesPt(IV)was synthesized according to a ligation reaction between cisPt(IV)and cholesterol(Scheme S1 in Supporting information).The yielded product was confirmed by exhaustive chemistry characterizations including FT-IR,1H NMR,ESI-MS,HPLC and elemental analysis(Figs.S1–S4 and Table S1 in Supporting information).The obtained cholesPt(IV)molecule was used as supplementary component to integrate with phospholipids of HSPC and PEGylated lipid for preparation of liposome(Fig.1a).A film hydration and membrane extrusion method was adopted to create liposome[34].Aiming for identification of an optimal condition for construction of cholesPt(IV)-functionalized liposomes,the liposome was prepared from constant quantity of phospholipids of HSPC and PEGylated lipid,but varied quantities of cholesPt(IV).The feed ratio of cholesPt(IV)and lipids was varied from 0.2:1 to 1:1.The integration efficiency of cholesPt(IV)into liposomes was quantified by ICP-MS measurement(Fig.1b).Apparently,high integration percentage of cholesPt(IV)could be achieved at relative low feed ratio of cholesPt(IV)/lipids.The total integration quantity calculated by the quantified integration percentage and the total feed quantity of cholesPt(IV),led to identification of an optimal formulation at cholesPt(IV)/lipid feed ratio of 0.4:1 to possess maximal cholesPt(IV)integration.

    The formulated structures were further transferred to dynamic light scattering(DLS)and zeta potential measurement.No marked difference in the size and surface charge was observed for the class of formulated liposomes irrespective of feed ratio of cholesPt(IV)/lipid,as evidenced by comparable diameters(ranging from 100 nm to 140 nm)and zeta potentials(ranging from-22 mV to-27 mV)(Table S2 in Supporting information).The identified liposome at cholesPt(IV)/lipid feed ratio of 0.4:1 was determined to possess an average diameter of 105.6 nm with unimodal polydispersity index of 0.07 by DLS measurement(Fig.1c).TEM of the liposome(0.4:1)also showed the similar formation as DLS(Fig.S5 in Supporting information).Furthermore,excellent colloidal stability of the formulated liposome was confirmed from the observation of constant DLS size over extended incubation(over 10 days)in PBS(Fig.1d).

    Fig.2. In vitro toxicity of diverse platinum formulations of cisPt(IV),cisplatin and CholesPt(IV)-Liposome in A2780 and A2780 DDP cells.Cell viability of A2780(a)and A2780 DDP(b)under treatment of cisPt(IV),cisplatin and cholesPt-NPs for 72 h.The IC50 of cisPt(IV),cisplatin and CholesPt(IV)-Liposome on A2780 and A2780 DDP cells at 72 h were shown in(c).(d)The drug resistance fold of each platinum drug formulation was calculated by the ratio of IC50 at A2780 DDP to IC50 at A2780.

    Prior to the drug potency test,it is important to demonstrate the proposed CholesPt(IV)-Liposome capable of releasing the active Pt(II)drugs inside the cells.Here,we evaluated the drug release rate from liposomes under diverse stimuli(presented inside the cells).Given that the cell interior is characterized as a distinctive reductive compartment(abundant existence of glutathione and ascorbic acids),the conversion of Pt(IV)derivatives to Pt(II)is presumed to be facilitated by means of redox-triggered release of two ligands and regeneration of the active Pt(II).In addition,nano-scaled structures are envisaged to internalize the cell through endocytosis pathway,followed by transfer to acidic endosome[35–37].In view of readily hydrolysis of Pt(IV)particularly in acidic milieu,it could be conjectured that the release of drug from liposome is facilitated in the subcellular endosome compartment.The subsequent investigations approved our speculation that both reductive treatment(ascorbate acid resembling the cell interior)and acidic treatment(pH 5 resembling the endosome pH)could stimulate the drug release.As opposed to negligible drug release at pH 7.4,liposome incubated at pH 5 exhibited markedly accelerated drug release profile.To our interest,liposome under treatment of ascorbate(10 mmol/L)exhibited most appreciable drug release profile(Fig.S6 in Supporting information).These results approved appealing characters of the proposed liposome that managed to preserve the drug payload in the formulation in the extracellular milieu but allow selective intracellular drug release of drug,which apparently is favorable in pursuit of minimized non-specific toxicity and premature drug detoxification.

    Fig.3.Impact of drug resistance on cellular uptake of diverse platinum derivatives.Quantification of intracellular platinum in A2780(a)and A2780 DDP(b)after 2 and 6 h drug incubation with cisplatin,cisPt(IV)and CholesPt(IV)-Liposome.The uptake-reducing index was summarized in(c).The uptake-reducing was defined as the ratio of platinum uptake at A2780 to platinum uptake at A2780 DDP.(d)Cellular uptake activity of CholesPt(IV)-Liposome at 37 and 4 °C.

    To validate the feasibility of the proposed CholesPt(IV)-Liposome in circumventing the drug resistance,a comparative study was conducted on the drug potency of diverse platinum derivatives to two types of human ovarian cancer cells,A2780(cisplatin susceptible cell line)and A2780 DDP(cisplatin resistant cell line).Cisplatin and cisPt(IV)were included as controls[cholesPt(IV)was not included in this study due to its poor solubility).Herein,the cells were treated by platinum drug derivatives at varying concentration for 72 h incubation(Figs.2a and b).The drug potency was assessed by measuring the cell viability relative to the control blank sample.Pertaining to the cisplatin-susceptible cell line of A2780,cisplatin was observed to exert most pronounced potency(IC50:2.7 μmol/L),whose IC50is markedly lower than that of cisPt(IV)(IC50:20.7 μmol/L)and CholesPt(IV)-Liposome(IC50:10.2 μmol/L)(Fig.2c).A plausible reason for the high potency of cisplatin[Pt(II)]over Pt(IV)derivatives should be attributed to the chemistry of Pt(IV)derivatives requiring additional step for activation of Pt(IV).Noteworthy was the significantly elevated drug potency of CholesPt(IV)-Liposome as compared to cisPt(IV).In respect to poor affinity of cisPt(IV)to the lipophilic cell membrane,most likely,the increased drug potency of CholesPt(IV)-Liposome could be accredited to its superior affinity to the cell membrane for promoted cellular uptake.The subsequent quantification of intracellular platinum by ICP-MS for the samples of cell lysis affirmed promoted internalization of CholesPt(IV)-Liposome as compared to cisPt(IV)(Fig.3a).

    Pertaining to cisplatin-resistant cell line of A2780 DDP,CholesPt(IV)-Liposome mediated notable potency,possessing an IC50of 12.6 μmol/L even exceeding the potency of cisplatin(IC5018.6 μmol/L)(Fig.2c).Close observation of the IC50values of cisplatin in A2780 and A2780 DDP identified the drug resistance characters of A2780 DDP substantially curtailed the drug potency of cisplatin,whose IC50was subjected to pronounced rise from 2.7 μmol/L in A2780 to 18.6 μmol/L in A2780 DDP(Fig.2c).The reduced drug potency of cisplatin may be attributable to the characteristic impeded drug internalization implicated in the drug resist cells.Of note,cisplatin is elucidated to translocate to the cell interior either through passive diffusion or active transportation with aids of cell membrane protein(copper transporter 1:Ctr1)[38].Molecular insight identified the reduced expression of Ctr1 protein in the platinum-resistant cells,which hampers the efficiency of the Ctr1-dependent cisplatin internalization.In accordance,quantification of intracellular platinum affirmed remarkably reduced internalization of cisplatin[also cisPt(IV)]at drug-resistant cell line.Particular noteworthy was reduced intracellular cisplatin at 6 h post incubation as compared to that at 2 h(Figs.3a–c),implying the critical impact of platinum-resistant cells,not only feasible of impeding internalization but also capable of prompting efflux of molecular platinum drugs.On the contrary,nanoparticles have been documented to steer an alternative endocytosis pathway rather than Ctr1-mediated transportation.Hence,the cell internalization of CholesPt(IV)-Liposome is envisioned to be unperturbed by the reduced expression of Ctr1 in the drug resistant cells,thereby capable of overcoming the impeded cellular uptake presented by drug resistant cells.Subsequent investigations approved CholesPt(IV)-Liposome capable of overcoming drug resistance,as evidenced by comparable drug potency of CholesPt(IV)-Liposome to A2780 and A2780 DDP,approximate 9.7 μmol/L for A2780 and 11.4 μmol/L for A2780 DDP,respectively(Figs.2c and d).In accordance to comparable IC50value of CholesPt(IV)-Liposome in A2780 and A2780 DDP,CholesPt(IV)-Liposome mediated similar level of cell uptake efficiency,which is in stark contrast to aforementioned cisplatin whose cell uptake efficiency was substantially lowered.These results suggest CholesPt(IV)-Liposome adopted an alternative pathway for cell internalization.CLSM observation for intracellular distribution of internalized CholesPt(IV)-Liposome captured colocalization of CholesPt(IV)-Liposome and endosome,confirmed the proposed CholesPt(IV)-Liposome internalized cell through endocytosis(Fig.S7 in Supporting information).Still,marked reduced cell uptake of CholesPt(IV)-Liposome at 4 °C as compared to 37 °C(Fig.3d),again affirmed CholesPt(IV)-Liposome internalized cells through an energy-dependent endocytosis pathway.Moreover,as opposed to aforementioned distinctive efflux character of A2780 DDP for cisplatin,the intracellular platinum was observed to progressive increase(Fig.3b),suggesting utilization of liposome by means of integration of lipophilic cholesPt(IV)prodrug in liposome could address the impeded cell internalization drawbacks of the molecular drugs encountered in drug resistant cells.

    For a quantitative evaluation of the capacity of proposed system in overcoming the drug resistance(impeded cellular uptake),the uptake-reducing index was calculated by quantification of the ratios of diverse platinum derivatives uptake level at A2780 to the uptake level at A2780 DDP.Higher value of uptake-reducing index stands for the crucial impact of drug resistance on impeding drug internalization.In agreement of drug potency evaluation,cisplatin showed highest uptake-resistance index(Fig.2d),suggesting its drug potency was markedly dwindled by the characters of drug resistant A2780.The molecular drug of cisPt(IV)also showed considerable high uptake resistance index,consistent with the previous claim that the drug resistance is versatile to a wide spectrum of molecular drugs.On the contrary,the uptake reducing index of CholesPt(IV)-Liposome is in proximity of 1,which approved appreciable strategy of manufacture of liposome as drug delivery vehicle to manage the impeded cell uptake schemed by drug resistant cells.

    Similarly,based on IC50values of diverse platinum drugs for A2780 and A2780 DDP(Fig.2c),the drug resistance index[defined by the ratio of IC50obtained for platinum-resistance cell line(A2780 DDP)to the IC50obtained for platinum-susceptible cell line(A2780)](Fig.2d)was calculated to characterize the capacity of diverse platinum drugs in overcoming drug resistance.In principal,lower drug resistance index,particularly approximate to 1(similar drug potency to platinum-susceptible cell line and platinum-resistant cell line),stands for higher capacity in overcoming the drug resistance.Overall,distinctive drug resistance was observed for cisplatin,as evidenced by high drug resistance index of 5(Fig.2d).Considerable drug resistance was also observed for Pt(IV),despite reduced drug resistance index of 2.3(Fig.2d).To our interest,CholesPt(IV)-Liposome afforded appreciable capacity in overcoming the drug resistance,whose drug resistance index is 1.2(Fig.2d).

    Fig.4. In vivo antitumor effects of CholesPt(IV)-Liposome.(a)Tumor growth curves of HCC PDX-bearing mice during the treatment process.(b)Body weight curves of mice.Weight(c)and image(d)of the tumors harvested from mice on day 10.???P <0.001.

    CholesPt(IV)-Liposome displayed stronger cytotoxicity than cisplatin and platinum(IV)at the same concentration(Fig.S8 in Supporting information).Inspired by the results of cytotoxicityin vitro,the antitumor effects of CholesPt(IV)-Liposome were further investigatedin vivo.We established a patient-derived xenograft(PDX)model of hepatocellular carcinoma(HCC)on BALB/c nude mice to reproduce the histological and microenvironmental features of tumor.Although cisplatin showed significant inhibition of tumor growth,the CholesPt(IV)-Liposome exhibited the best antitumor efficacy,with an inhibitory rate of 80.7% compared to the saline group(Figs.4a and d).Notably,the mice treated with cisplatin were observed apparent toxic side effects.In detail,the reduced weights of the mice failed to return to the normal level at the end of treatment.The body weights of CholesPt(IV)-Liposome-treated mice,however,were no apparent changes(Fig.4b).Mice treated with CholesPt(IV)-Liposome had smaller tumors(0.53 ± 0.11 g),which was 1/3 that of tumors from mice received PBS treatment(1.67 ± 0.36 g)(Fig.4c).These results indicate that CholesPt(IV)-Liposome had stronger antitumor efficacy but with lower systemic toxicity.

    Hematoxylin and eosin(H&E),TdT-mediated dUTP Nick-End Labeling(TUNEL)-staining,and immunofluorescence analysis of tumor tissues results revealed that CholesPt(IV)-Liposome could cause more necrosis and apoptosis,as well as damaged DNA strands(Fig.5a),which demonstrated that CholesPt(IV)-Liposome had superior antitumor effects.In addition,there was no obvious histological toxicity in main organs(heart,liver,spleen,lung,and kidney)and blood biochemistry,which indicated the excellent biocompatibility of CholesPt(IV)-Liposome(Fig.5b and Fig.S9 in Supporting information).

    We further explored the antitumor mechanism of CholesPt(IV)-Liposome by western blotting.Compared with cisplatin or platinum(IV),the CholesPt(IV)-Liposome-treated cells exhibited marked up-regulation of apoptosis-related proteins,such as cleaved caspase 3(abbreviated as C-Caspase 3),P53,Bax,as well as decreased anti-apoptosis protein Bcl-2(Figs.6a and b).Compared with cisplatin and platinum(IV),the CholesPt(IV)-Liposome could lead to increased expression of cleaved PARP(abbreviated as CPARP)andγ-H2A.X,which suggested that CholesPt(IV)-Liposome could effectively cause DNA damages(Figs.6c and d).

    Fig.5.Therapeutic efficacy and biocompatibility evaluation of CholesPt(IV)-Liposome on HCC PDX models.(a)H&E staining,immunohistochemistry of TUNEL(brown),and γ-H2A.X(green)analyses of tumor sections.Scale bar:50 μm.(b)Biochemical analysis of serum after the treatments on 10 d.

    Fig.6.Antitumor mechanism investigation of CholesPt(IV)-Liposome.Western blot analysis(a)and quantification(b)of antitumor-associated proteins in HepG2 cells after various treatments.Western blot analysis(c)and quantification(d)of DNA damage related proteins.*P <0.05,**P <0.01,***P <0.001.

    To this end,we demonstrated a valid strategy of coupling Pt(IV)prodrug to a lipophilic cholesterol for fabrication of CholesPt(IV)-Liposome.The subsequent investigations explicated the proposed formulation capable of promoting cell internalization of platinum prodrug.CholesPt(IV)-Liposome possessed a higher cytotoxicity against the cancer cells in comparison with cisplatin.In addition,CholesPt(IV)-Liposome induced a substantial decrease in the size of patient-derived xenograft tumors of hepatocellular carcinoma in mice.Furthermore,CholesPt(IV)-Liposome had lower toxicity to normal organs,revealing it’s good biocompatibility.In view of its appreciable competence in improving platinum efficiency and reducing side effects,the proposed formulation should be emphasized as a worthy strategy in development of potent platinum delivery systems for cancer treatment.

    Declaration of competing interest

    The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

    Acknowledgments

    This work was financially supported by the GDNRC[Guangdong Nature Resource Center](2020)(037),National Natural Science Foundation of China(Nos.81773642,52073139),the Natural Science Foundation of Guangdong Province(No.2019A1515011619),Guangdong Provincial Science and Technology Department(No.2016A030311015),the Key R &D Plan of Chenzhou(No.ZDYF202008),and the Discipline Leader Startup Fund of Huazhong University of Science and Technoloy Union Shenzhen Hospital(No.YN2021002).BABL/c nude mice are used in accordance with the guidelines of ICE for Clinical Research and Animal Trials of the First Affiliated Hospital of Sun Yat-sen University Approval Letter for Research Protocol(No.2018240).

    Supplementary materials

    Supplementary material associated with this article can be found,in the online version,at doi:10.1016/j.cclet.2021.10.077.

    日韩制服骚丝袜av| 国产日韩欧美亚洲二区| 亚洲一级一片aⅴ在线观看| 美女主播在线视频| 狠狠婷婷综合久久久久久88av| 亚洲,欧美精品.| 老司机亚洲免费影院| av网站在线播放免费| 中文字幕人妻丝袜一区二区 | 日韩中文字幕视频在线看片| 一级,二级,三级黄色视频| 男女午夜视频在线观看| 午夜福利视频精品| 精品久久久久久电影网| 色94色欧美一区二区| 熟妇人妻不卡中文字幕| 男男h啪啪无遮挡| 爱豆传媒免费全集在线观看| 汤姆久久久久久久影院中文字幕| 亚洲国产日韩一区二区| 三上悠亚av全集在线观看| 欧美人与性动交α欧美软件| 中国国产av一级| 午夜av观看不卡| 久久久精品免费免费高清| a级毛片黄视频| 精品国产一区二区久久| 日韩av不卡免费在线播放| 人体艺术视频欧美日本| 欧美黄色片欧美黄色片| 秋霞伦理黄片| 欧美97在线视频| 午夜精品国产一区二区电影| 国产综合精华液| freevideosex欧美| 捣出白浆h1v1| 欧美亚洲日本最大视频资源| 午夜日韩欧美国产| 性色avwww在线观看| 国产人伦9x9x在线观看 | 丰满乱子伦码专区| 制服诱惑二区| 永久免费av网站大全| 日韩,欧美,国产一区二区三区| 国产不卡av网站在线观看| 一区福利在线观看| 国产亚洲精品第一综合不卡| 久久久久久久大尺度免费视频| 一级黄片播放器| 国产精品熟女久久久久浪| 亚洲综合色惰| 91精品三级在线观看| 国产免费视频播放在线视频| 两性夫妻黄色片| 国产白丝娇喘喷水9色精品| 久久久久久免费高清国产稀缺| 精品午夜福利在线看| 亚洲精品视频女| 亚洲在久久综合| 女性被躁到高潮视频| av不卡在线播放| 精品第一国产精品| 在线观看三级黄色| 女人精品久久久久毛片| 菩萨蛮人人尽说江南好唐韦庄| 日本色播在线视频| 欧美日韩精品成人综合77777| 免费高清在线观看视频在线观看| 最近最新中文字幕大全免费视频 | 日日撸夜夜添| 免费看不卡的av| 侵犯人妻中文字幕一二三四区| 啦啦啦中文免费视频观看日本| 熟女少妇亚洲综合色aaa.| 免费人妻精品一区二区三区视频| 国产淫语在线视频| 在线免费观看不下载黄p国产| 日日爽夜夜爽网站| 有码 亚洲区| 美女主播在线视频| 日韩人妻精品一区2区三区| 女人久久www免费人成看片| av视频免费观看在线观看| 十八禁高潮呻吟视频| 女性被躁到高潮视频| 我的亚洲天堂| 国产人伦9x9x在线观看 | 人妻人人澡人人爽人人| 亚洲精品乱久久久久久| 国产精品成人在线| 亚洲精品久久成人aⅴ小说| 亚洲图色成人| 国产乱来视频区| 久久久久国产精品人妻一区二区| 亚洲国产色片| 色婷婷久久久亚洲欧美| 国产精品嫩草影院av在线观看| 婷婷色综合www| 欧美人与性动交α欧美软件| 欧美另类一区| 香蕉国产在线看| 国产成人精品无人区| 性高湖久久久久久久久免费观看| 人妻一区二区av| 蜜桃在线观看..| 18禁动态无遮挡网站| 欧美 日韩 精品 国产| 日韩制服丝袜自拍偷拍| 高清在线视频一区二区三区| 免费少妇av软件| 少妇被粗大的猛进出69影院| 精品人妻熟女毛片av久久网站| 赤兔流量卡办理| 精品一区二区三卡| 两个人免费观看高清视频| 午夜免费男女啪啪视频观看| 少妇的逼水好多| 婷婷色av中文字幕| 国产av精品麻豆| 亚洲av在线观看美女高潮| 久久精品国产亚洲av天美| 国产成人a∨麻豆精品| 精品一区二区三区四区五区乱码 | 蜜桃在线观看..| 精品视频人人做人人爽| 天天躁夜夜躁狠狠躁躁| 18禁动态无遮挡网站| 黑人巨大精品欧美一区二区蜜桃| 久久精品国产鲁丝片午夜精品| 涩涩av久久男人的天堂| 欧美97在线视频| 午夜免费观看性视频| 国产精品国产av在线观看| 亚洲国产精品国产精品| 久久久精品区二区三区| 国产成人av激情在线播放| 国产成人精品婷婷| 欧美精品一区二区免费开放| 免费观看在线日韩| 精品少妇黑人巨大在线播放| 久久精品aⅴ一区二区三区四区 | 极品少妇高潮喷水抽搐| 秋霞在线观看毛片| 亚洲国产最新在线播放| 国产综合精华液| 国产精品三级大全| 中文字幕色久视频| 日韩一卡2卡3卡4卡2021年| 久久精品国产自在天天线| 免费观看a级毛片全部| 亚洲精品日韩在线中文字幕| 这个男人来自地球电影免费观看 | a级片在线免费高清观看视频| videos熟女内射| 中文字幕亚洲精品专区| 久久久久精品性色| 春色校园在线视频观看| 一区二区三区乱码不卡18| 高清欧美精品videossex| 一本大道久久a久久精品| 曰老女人黄片| 欧美日韩av久久| 精品国产超薄肉色丝袜足j| www.自偷自拍.com| 黄色 视频免费看| 97精品久久久久久久久久精品| 王馨瑶露胸无遮挡在线观看| 啦啦啦视频在线资源免费观看| 久久 成人 亚洲| 午夜91福利影院| 免费在线观看视频国产中文字幕亚洲 | 五月天丁香电影| 久久久久精品性色| 一区二区三区激情视频| 91精品国产国语对白视频| 国产成人av激情在线播放| 国产免费一区二区三区四区乱码| 精品久久久久久电影网| 男人操女人黄网站| 国产精品av久久久久免费| 久久人妻熟女aⅴ| 国产黄色免费在线视频| 一区二区三区精品91| 日韩制服骚丝袜av| 1024视频免费在线观看| 欧美+日韩+精品| videos熟女内射| 在线观看人妻少妇| 国产黄色视频一区二区在线观看| 久久精品久久精品一区二区三区| 国产综合精华液| 中国三级夫妇交换| 久久午夜综合久久蜜桃| 最新中文字幕久久久久| 日韩大片免费观看网站| 国产麻豆69| 亚洲综合色网址| 久久热在线av| 国产在视频线精品| 丝袜脚勾引网站| 女人高潮潮喷娇喘18禁视频| 一区二区日韩欧美中文字幕| 黄色配什么色好看| 黄频高清免费视频| 香蕉国产在线看| 成年女人毛片免费观看观看9 | 99热全是精品| av线在线观看网站| 在线观看免费视频网站a站| 1024香蕉在线观看| 精品国产一区二区三区久久久樱花| 在线观看免费日韩欧美大片| 少妇的丰满在线观看| 观看美女的网站| 一区二区三区乱码不卡18| 久久久精品区二区三区| 亚洲精品久久成人aⅴ小说| 久久久久久久久久久免费av| 美女大奶头黄色视频| 观看av在线不卡| 丰满乱子伦码专区| a 毛片基地| 久久久国产欧美日韩av| 视频在线观看一区二区三区| 美女福利国产在线| 欧美97在线视频| 国产精品偷伦视频观看了| 毛片一级片免费看久久久久| 在线观看免费视频网站a站| 男人操女人黄网站| 不卡av一区二区三区| 国产午夜精品一二区理论片| 国产极品粉嫩免费观看在线| 2021少妇久久久久久久久久久| 日韩在线高清观看一区二区三区| 日韩制服骚丝袜av| 一级a爱视频在线免费观看| 日韩,欧美,国产一区二区三区| 一级毛片 在线播放| 少妇 在线观看| 国产精品.久久久| 大片电影免费在线观看免费| 国产精品久久久久久精品古装| 国产有黄有色有爽视频| 中文字幕最新亚洲高清| 精品人妻一区二区三区麻豆| 视频在线观看一区二区三区| 精品少妇内射三级| 国产精品香港三级国产av潘金莲 | 叶爱在线成人免费视频播放| 国产人伦9x9x在线观看 | 亚洲av福利一区| 久久久久久免费高清国产稀缺| 精品国产露脸久久av麻豆| 久久久久人妻精品一区果冻| 老女人水多毛片| 亚洲精品自拍成人| 咕卡用的链子| 亚洲,欧美精品.| 桃花免费在线播放| 国产精品国产三级国产专区5o| 国产高清不卡午夜福利| 中国国产av一级| 国产野战对白在线观看| 青草久久国产| 春色校园在线视频观看| 亚洲精品美女久久久久99蜜臀 | 汤姆久久久久久久影院中文字幕| 精品久久久精品久久久| 欧美老熟妇乱子伦牲交| 少妇的丰满在线观看| 国产无遮挡羞羞视频在线观看| 肉色欧美久久久久久久蜜桃| 看免费av毛片| 久久精品aⅴ一区二区三区四区 | 建设人人有责人人尽责人人享有的| 人人妻人人澡人人爽人人夜夜| 国产精品三级大全| 高清在线视频一区二区三区| 欧美精品一区二区免费开放| 亚洲一区中文字幕在线| 精品酒店卫生间| 一级毛片电影观看| 久久精品国产亚洲av天美| 丝袜人妻中文字幕| 99久久精品国产国产毛片| 少妇精品久久久久久久| 精品人妻偷拍中文字幕| 性色avwww在线观看| 欧美人与善性xxx| 亚洲国产欧美在线一区| 秋霞在线观看毛片| 欧美xxⅹ黑人| av卡一久久| 久久亚洲国产成人精品v| 亚洲成国产人片在线观看| 欧美亚洲日本最大视频资源| 天天躁夜夜躁狠狠久久av| 国产成人a∨麻豆精品| 18+在线观看网站| 日日撸夜夜添| 亚洲国产成人一精品久久久| 丝袜人妻中文字幕| 色婷婷久久久亚洲欧美| 午夜福利在线免费观看网站| av一本久久久久| 涩涩av久久男人的天堂| 最黄视频免费看| 亚洲精品第二区| 叶爱在线成人免费视频播放| 黄色毛片三级朝国网站| 伦精品一区二区三区| 国产成人精品婷婷| 新久久久久国产一级毛片| 成人黄色视频免费在线看| 亚洲一区中文字幕在线| 国产av码专区亚洲av| 亚洲精品久久午夜乱码| 另类亚洲欧美激情| 中国三级夫妇交换| 自线自在国产av| 久久99蜜桃精品久久| 9热在线视频观看99| 国产精品av久久久久免费| 久久精品久久精品一区二区三区| 日韩在线高清观看一区二区三区| 日韩av免费高清视频| 精品亚洲乱码少妇综合久久| av免费观看日本| 国产精品99久久99久久久不卡 | 精品国产一区二区久久| 热re99久久精品国产66热6| 伊人亚洲综合成人网| 好男人视频免费观看在线| 亚洲精品美女久久久久99蜜臀 | 少妇人妻久久综合中文| 亚洲精品国产av蜜桃| 亚洲av中文av极速乱| 热99国产精品久久久久久7| 国产成人精品在线电影| 亚洲精品久久午夜乱码| 欧美激情 高清一区二区三区| 日韩av免费高清视频| 国产亚洲av片在线观看秒播厂| 国产极品粉嫩免费观看在线| 黄色 视频免费看| 国产精品国产三级专区第一集| 在现免费观看毛片| 中文字幕人妻丝袜制服| 男男h啪啪无遮挡| 不卡视频在线观看欧美| 久久综合国产亚洲精品| 久久久欧美国产精品| 国产亚洲欧美精品永久| 亚洲第一av免费看| 一二三四在线观看免费中文在| 色网站视频免费| av国产精品久久久久影院| 国产伦理片在线播放av一区| 欧美另类一区| 久久这里有精品视频免费| 久久精品久久久久久噜噜老黄| 热re99久久精品国产66热6| 午夜日本视频在线| 狂野欧美激情性bbbbbb| 久久人妻熟女aⅴ| 亚洲欧美一区二区三区久久| 欧美最新免费一区二区三区| 毛片一级片免费看久久久久| 女人久久www免费人成看片| 国产综合精华液| kizo精华| 国产高清国产精品国产三级| 18+在线观看网站| √禁漫天堂资源中文www| 久久久久久久亚洲中文字幕| 久久久久视频综合| 国产在线一区二区三区精| 欧美日韩精品成人综合77777| 国产无遮挡羞羞视频在线观看| 汤姆久久久久久久影院中文字幕| 99热全是精品| 欧美亚洲 丝袜 人妻 在线| 97精品久久久久久久久久精品| 永久免费av网站大全| 热99国产精品久久久久久7| 你懂的网址亚洲精品在线观看| 久久韩国三级中文字幕| 精品酒店卫生间| av国产精品久久久久影院| 亚洲在久久综合| 天堂8中文在线网| 日韩在线高清观看一区二区三区| 青春草亚洲视频在线观看| 亚洲视频免费观看视频| 国产日韩一区二区三区精品不卡| 尾随美女入室| 青青草视频在线视频观看| 欧美黄色片欧美黄色片| 综合色丁香网| 日韩,欧美,国产一区二区三区| 色视频在线一区二区三区| 亚洲,欧美,日韩| 国产一区二区 视频在线| 欧美老熟妇乱子伦牲交| 欧美日韩视频高清一区二区三区二| 亚洲国产精品999| 搡老乐熟女国产| kizo精华| 综合色丁香网| 在线天堂中文资源库| 精品第一国产精品| 久久精品国产亚洲av涩爱| 黄色怎么调成土黄色| 精品人妻熟女毛片av久久网站| 天美传媒精品一区二区| 欧美激情极品国产一区二区三区| 日日摸夜夜添夜夜爱| 大香蕉久久网| av卡一久久| 久久国产精品大桥未久av| av国产久精品久网站免费入址| 欧美日本中文国产一区发布| 在线观看免费高清a一片| 久久精品人人爽人人爽视色| 一区二区三区乱码不卡18| 一级毛片黄色毛片免费观看视频| 五月天丁香电影| 欧美精品一区二区大全| 精品少妇一区二区三区视频日本电影 | 欧美+日韩+精品| 校园人妻丝袜中文字幕| 国产精品.久久久| 大片免费播放器 马上看| 日韩熟女老妇一区二区性免费视频| 亚洲成人手机| av.在线天堂| 色婷婷久久久亚洲欧美| 亚洲激情五月婷婷啪啪| 建设人人有责人人尽责人人享有的| 成人手机av| 亚洲国产欧美日韩在线播放| 精品一区二区三区四区五区乱码 | 卡戴珊不雅视频在线播放| 色94色欧美一区二区| 午夜91福利影院| 狠狠婷婷综合久久久久久88av| 女性被躁到高潮视频| 精品人妻偷拍中文字幕| 久久精品久久久久久久性| 哪个播放器可以免费观看大片| 国产爽快片一区二区三区| 人人妻人人澡人人看| 女人高潮潮喷娇喘18禁视频| 大片电影免费在线观看免费| 蜜桃在线观看..| 日韩成人av中文字幕在线观看| 99re6热这里在线精品视频| 91久久精品国产一区二区三区| 1024香蕉在线观看| 日日爽夜夜爽网站| 你懂的网址亚洲精品在线观看| 男人爽女人下面视频在线观看| 久久久久久久久久久久大奶| 亚洲精品在线美女| 日韩不卡一区二区三区视频在线| 欧美精品高潮呻吟av久久| av网站在线播放免费| 午夜免费男女啪啪视频观看| 亚洲色图综合在线观看| 99精国产麻豆久久婷婷| 丝袜脚勾引网站| 一区二区三区精品91| 在线亚洲精品国产二区图片欧美| 日韩大片免费观看网站| 国产av一区二区精品久久| 国产成人av激情在线播放| 久久久国产精品麻豆| 又黄又粗又硬又大视频| 午夜日本视频在线| 在线亚洲精品国产二区图片欧美| 亚洲一级一片aⅴ在线观看| 美女中出高潮动态图| 男女国产视频网站| 久久久久国产网址| 丰满少妇做爰视频| 美女大奶头黄色视频| 啦啦啦啦在线视频资源| 日本wwww免费看| 欧美在线黄色| 久久人人爽av亚洲精品天堂| 国产高清不卡午夜福利| 黄色视频在线播放观看不卡| 午夜av观看不卡| 亚洲精品一区蜜桃| 国产激情久久老熟女| 人人妻人人爽人人添夜夜欢视频| 王馨瑶露胸无遮挡在线观看| 交换朋友夫妻互换小说| 韩国高清视频一区二区三区| 国产一区二区在线观看av| 精品一区二区三卡| 国产成人av激情在线播放| 国产高清不卡午夜福利| 国产精品99久久99久久久不卡 | 人人澡人人妻人| 成人免费观看视频高清| 老司机影院成人| 亚洲av中文av极速乱| 午夜精品国产一区二区电影| 亚洲国产欧美在线一区| 国产成人一区二区在线| 亚洲国产欧美网| 亚洲国产精品一区二区三区在线| 韩国高清视频一区二区三区| 色婷婷av一区二区三区视频| 在线观看免费视频网站a站| 天美传媒精品一区二区| 肉色欧美久久久久久久蜜桃| 黄网站色视频无遮挡免费观看| 少妇人妻 视频| 久久狼人影院| 91在线精品国自产拍蜜月| 国产有黄有色有爽视频| 日韩一区二区三区影片| 精品一区二区免费观看| 赤兔流量卡办理| 国产免费视频播放在线视频| 亚洲精品aⅴ在线观看| 婷婷成人精品国产| 可以免费在线观看a视频的电影网站 | 欧美老熟妇乱子伦牲交| 王馨瑶露胸无遮挡在线观看| 91午夜精品亚洲一区二区三区| 国产欧美日韩一区二区三区在线| 欧美精品国产亚洲| 老汉色av国产亚洲站长工具| 欧美 亚洲 国产 日韩一| 视频在线观看一区二区三区| av线在线观看网站| 欧美少妇被猛烈插入视频| 国产在线免费精品| 亚洲国产精品成人久久小说| 最黄视频免费看| 美女午夜性视频免费| 观看美女的网站| 狠狠婷婷综合久久久久久88av| 青春草国产在线视频| av片东京热男人的天堂| 18禁国产床啪视频网站| 久久久久久久亚洲中文字幕| 两个人看的免费小视频| 香蕉丝袜av| 99热全是精品| av片东京热男人的天堂| 欧美老熟妇乱子伦牲交| 国语对白做爰xxxⅹ性视频网站| 2022亚洲国产成人精品| av在线app专区| 制服人妻中文乱码| 亚洲av电影在线进入| 免费黄色在线免费观看| 国产成人91sexporn| kizo精华| 一本久久精品| 中文欧美无线码| 涩涩av久久男人的天堂| 国产一区二区 视频在线| 欧美激情高清一区二区三区 | 日韩在线高清观看一区二区三区| 亚洲欧美一区二区三区久久| 超色免费av| videos熟女内射| 亚洲情色 制服丝袜| 一级毛片黄色毛片免费观看视频| 精品国产超薄肉色丝袜足j| 久久久久视频综合| 国产在线视频一区二区| 9热在线视频观看99| 日韩不卡一区二区三区视频在线| 国产av一区二区精品久久| 好男人视频免费观看在线| 亚洲精品久久久久久婷婷小说| 国产亚洲精品第一综合不卡| 青青草视频在线视频观看| 国产成人精品久久久久久| 久久久久久久大尺度免费视频| 日本猛色少妇xxxxx猛交久久| 性高湖久久久久久久久免费观看| 在线 av 中文字幕| 91aial.com中文字幕在线观看| 午夜影院在线不卡| 亚洲,一卡二卡三卡| 母亲3免费完整高清在线观看 | 在线观看免费日韩欧美大片| 久久久久久久亚洲中文字幕| 一区二区三区四区激情视频| 精品福利永久在线观看| 久久精品国产亚洲av天美| 久久影院123| 亚洲欧美一区二区三区黑人 | 成人国产av品久久久| 亚洲久久久国产精品| 女性被躁到高潮视频| 视频区图区小说| 18禁国产床啪视频网站| 2021少妇久久久久久久久久久| 99香蕉大伊视频| 久久毛片免费看一区二区三区| 国产在视频线精品| av免费观看日本| 80岁老熟妇乱子伦牲交| 一本久久精品| 欧美日韩精品成人综合77777| 少妇被粗大的猛进出69影院|